Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Clinical Oncology
This open-label, randomized phase II-III study of 191 patients with locally advanced or metastatic BTC compared triplet therapy of oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), with doublet therapy consisting of cisplatin and gemcitabine (CISGEM). Triplet therapy did not outperform doublet therapy in this study.
Hematology/Oncology January 25th 2022
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH